416 related articles for article (PubMed ID: 24742768)
1. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768
[TBL] [Abstract][Full Text] [Related]
2. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.
Lichtblau M; Harzheim D; Ehlken N; Marra A; Pinado FP; Grünig E; Egenlauf B
Lung; 2015 Feb; 193(1):105-12. PubMed ID: 25318865
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.
Levin YD; White RJ
Drugs Today (Barc); 2011 Feb; 47(2):145-56. PubMed ID: 21431102
[TBL] [Abstract][Full Text] [Related]
5. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
Oudiz RJ; Brundage BH; Galiè N; Ghofrani HA; Simonneau G; Botros FT; Chan M; Beardsworth A; Barst RJ;
J Am Coll Cardiol; 2012 Aug; 60(8):768-74. PubMed ID: 22818063
[TBL] [Abstract][Full Text] [Related]
6. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.
Udeoji DU; Schwarz ER
Ther Adv Respir Dis; 2013 Feb; 7(1):39-49. PubMed ID: 23129569
[TBL] [Abstract][Full Text] [Related]
7. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
8. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Arif SA; Poon H
Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
[TBL] [Abstract][Full Text] [Related]
9. Initial experience with tadalafil in pediatric pulmonary arterial hypertension.
Takatsuki S; Calderbank M; Ivy DD
Pediatr Cardiol; 2012 Jun; 33(5):683-8. PubMed ID: 22402804
[TBL] [Abstract][Full Text] [Related]
10. Tadalafil for the treatment of pulmonary arterial hypertension.
Rosenzweig EB
Expert Opin Pharmacother; 2010 Jan; 11(1):127-32. PubMed ID: 20001434
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
12. Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations.
Shlobin OA; Brown AW; Weir N; Ahmad S; Lemma M; Nathan SD
Lung; 2012 Oct; 190(5):573-8. PubMed ID: 22797830
[TBL] [Abstract][Full Text] [Related]
13. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
15. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
17. Tadalafil for the treatment of pulmonary arterial hypertension.
Klinger JR
Expert Rev Respir Med; 2011 Jun; 5(3):315-28. PubMed ID: 21702653
[TBL] [Abstract][Full Text] [Related]
18. Treatment of canine pulmonary arterial hypertension: is tadalafil an appropriate alternative to sildenafil?
Wung D
Int J Pharm Compd; 2013; 17(1):24-7. PubMed ID: 23627243
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
[TBL] [Abstract][Full Text] [Related]
20. [Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].
Kiliçkesmez K; Küçükoğlu MS
Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():16-8. PubMed ID: 20819751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]